scispace - formally typeset
Search or ask a question
Author

Simone Tresoldi

Bio: Simone Tresoldi is an academic researcher. The author has contributed to research in topics: Acute coronary syndrome & Percutaneous coronary intervention. The author has an hindex of 8, co-authored 12 publications receiving 1484 citations.

Papers
More filters
Journal ArticleDOI
TL;DR: In patients with an acute coronary syndrome, the rates of major adverse cardiovascular events and net adverse clinical events were not significantly lower with bivalirudin than with unfractionated heparin.
Abstract: BACKGROUND Conflicting evidence exists on the efficacy and safety of bivalirudin administered as part of percutaneous coronary intervention (PCI) in patients with an acute coronary syndrome METHODS We randomly assigned 7213 patients with an acute coronary syndrome for whom PCI was anticipated to receive either bivalirudin or unfractionated heparin Patients in the bivalirudin group were subsequently randomly assigned to receive or not to receive a post-PCI bivalirudin infusion Primary outcomes for the comparison between bivalirudin and heparin were the occurrence of major adverse cardiovascular events (a composite of death, myocardial infarction, or stroke) and net adverse clinical events (a composite of major bleeding or a major adverse cardiovascular event) The primary outcome for the comparison of a post-PCI bivalirudin infusion with no post-PCI infusion was a composite of urgent target-vessel revascularization, definite stent thrombosis, or net adverse clinical events RESULTS The rate of major adverse cardiovascular events was not significantly lower with bivalirudin than with heparin (103% and 109%, respectively; relative risk, 094; 95% confidence interval [CI], 081 to 109; P = 044), nor was the rate of net adverse clinical events (112% and 124%, respectively; relative risk, 089; 95% CI, 078 to 103; P = 012) Post-PCI bivalirudin infusion, as compared with no infusion, did not significantly decrease the rate of urgent target-vessel revascularization, definite stent thrombosis, or net adverse clinical events (110% and 119%, respectively; relative risk, 091; 95% CI, 074 to 111; P = 034) CONCLUSIONS In patients with an acute coronary syndrome, the rates of major adverse cardiovascular events and net adverse clinical events were not significantly lower with bivalirudin than with unfractionated heparin The rate of the composite of urgent target-vessel revascularization, definite stent thrombosis, or net adverse clinical events was not significantly lower with a post-PCI bivalirudin infusion than with no post-PCI infusion (Funded by the Medicines Company and Terumo Medical; MATRIX ClinicalTrialsgov number, NCT01433627) abstr act

322 citations

Journal ArticleDOI
Marco Valgimigli1, Enrico Frigoli1, Sergio Leonardi, Pascal Vranckx, Martina Rothenbühler1, Matteo Tebaldi, Ferdinando Varbella, Paolo Calabrò2, Stefano Garducci, Paolo Rubartelli, Carlo Briguori, Giuseppe Andò3, Maurizio Ferrario, Ugo Limbruno, Roberto Garbo, Paolo Sganzerla, Filippo Russo, Marco Stefano Nazzaro, Alessandro Lupi, Bernardo Cortese, Arturo Ausiello, Salvatore Ierna, Giovanni Esposito4, Giuseppe Ferrante, Andrea Santarelli, Gennaro Sardella5, Nicoletta De Cesare, Paolo Tosi, Arnoud W J van 't Hof6, Elmir Omerovic7, Salvatore Brugaletta8, Stephan Windecker1, Dik Heg1, Peter Jüni9, Gianluca Campo9, Lucia Uguccioni, Corrado Tamburino, Patrizia Presbitero, Dennis Zavalloni-Parenti, Fabio Ferrari, Roberto Ceravolo, Fabio Tarantino, Giampaolo Pasquetto, Gavino Casu, Stefano Mameli, Maria Letizia Stochino, Pietro Mazzarotto, Alberto Cremonesi, Francesco Saia, Giovanni Saccone, Fabio Abate, Andrea Picchi, Roberto Violini, Salvatore Colangelo, Giacomo Boccuzzi, Vincenzo Guiducci, Carlo Vigna, Antonio Zingarelli, Andrea Gagnor, Tiziana Zaro, Simone Tresoldi, Pietro Vandoni, Marco Contarini, Armando Liso, Dellavalle A, Salvatore Curello, Fabio Mangiacapra, Rosario Evola, Cataldo Palmieri, Camillo Falcone, Francesco Liistro, Manuela Creaco, Antonio Colombo, Alaide Chieffo, Andrea Perkan, Stefano De Servi, Dionigi Fischetti, Stefano Rigattieri, Alessandro Sciahbasi, Edoardo Pucci, Enrico Romagnoli, Claudio Moretti, Luciano Moretti, Raffaele De Caterina, Marcello Caputo, Marco Zimmarino, Ezio Bramucci, Emilio Di Lorenzo, Maurizio Turturo, Roberto Bonmassari, Carlo Penzo, Bruno Loi, Ciro Mauro, Anna Sonia Petronio, Gabriele Gabrielli, Antonio Micari, Flavia Belloni, Francesco Amico, Marco Comeglio, Claudio Fresco, Isala Klinieken, Nicolas M. Van Mieghem, Roberto Diletti, Evelyn Regar, Manel Sabaté, José Francisco Díaz Fernández, Vicente Mainar, José M. de la Torre Hernández 
TL;DR: The prespecified final 1-year outcomes of the MATRIX programme, designed to assess the comparative safety and effectiveness of radial versus femoral access and of bivalirudin versus unfractionated heparin with optional glycoprotein IIb/IIIa inhibitors in patients with the whole spectrum of acute coronary syndrome undergoing invasive management, are described.

211 citations

Journal ArticleDOI
TL;DR: Stress echocardiography is a feasible, safe, and effective tool for early stratification of patients admitted to the ER with acute chest pain and non-ischemic ECG and resting echo.

68 citations

Journal ArticleDOI
27 Sep 2016-BMJ
TL;DR: A bivalirudin monotherapy strategy compared with heparin with or without glycoprotein IIb/IIIa inhibitors, did not result in reduced major adverse cardiovascular events or net adverse clinical events in patients with orwithout ST segment elevation.
Abstract: Objective To test the optimal antithrombotic regimen in patients with acute coronary syndrome. Design Randomised controlled trial. Setting Patients with acute coronary syndrome with and without ST segment elevation in 78 centres in Italy, the Netherlands, Spain, and Sweden. Participants 7213 patients with acute coronary syndrome and planned percutaneous coronary intervention: 4010 with ST segment elevation and 3203 without ST segment elevation. The primary study results in the overall population have been reported previously. Interventions Patients were randomly assigned, in an open label fashion, to one of two regimens: bivalirudin with glycoprotein IIb/IIIa inhibitors restricted to procedural complications or heparin with or without glycoprotein IIb/IIIa inhibitors. Main outcome measures Primary endpoints were the occurrence of major adverse cardiovascular events, defined as death, myocardial infarction or stroke; and net adverse clinical events, defined as major bleeding or major adverse cardiovascular events, both assessed at 30 days. Analyses were performed by the principle of intention to treat. Results Use of a glycoprotein IIb/IIIa inhibitor in patients assigned to heparin was planned at baseline in 30.7% of patients with ST segment elevation, in 10.9% without ST segment elevation, and in no patients assigned to bivalirudin. In patients with ST segment elevation, major adverse cardiovascular events occurred in 118 (5.9%) assigned to bivalirudin and 129 (6.5%) assigned to heparin (rate ratio 0.90, 95% confidence interval 0.70 to 1.16; P=0.43), whereas net adverse clinical events occurred in 139 (7.0%) patients assigned to bivalirudin and 163 (8.2%) assigned to heparin (0.84, 0.67 to 1.05; P=0.13). In patients without ST segment elevation, major adverse cardiovascular events occurred in 253 (15.9%) assigned to bivalirudin and 262 (16.4%) assigned to heparin (0.97, 0.80 to 1.17; P=0.74), whereas net adverse clinical events occurred in 262 (16.5%) patients assigned to bivalirudin and 281 (17.6%) assigned to heparin (0.93, 0.77 to 1.12; P=0.43). Conclusions A bivalirudin monotherapy strategy compared with heparin with or without glycoprotein IIb/IIIa inhibitors, did not result in reduced major adverse cardiovascular events or net adverse clinical events in patients with or without ST segment elevation. Trial Registration ClinicalTrials.gov NCT01433627.

49 citations


Cited by
More filters
Journal ArticleDOI
TL;DR: 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation are published.
Abstract: 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)

6,599 citations

Journal ArticleDOI
TL;DR: Authors/Task Force Members: Franz-Josef Neumann* (ESC Chairperson) (Germany), Miguel Sousa-Uva* (EACTS Chair person) (Portugal), Anders Ahlsson (Sweden), Fernando Alfonso (Spain), Adrian P. Banning (UK), Umberto Benedetto (UK).

4,342 citations

Journal ArticleDOI
TL;DR: Neumann et al. as discussed by the authors proposed a task force to evaluate the EACTS Review Co-ordinator's work on gender equality in the context of women's reproductive health.
Abstract: Authors/Task Force Members: Franz-Josef Neumann* (ESC Chairperson) (Germany), Miguel Sousa-Uva* (EACTS Chairperson) (Portugal), Anders Ahlsson (Sweden), Fernando Alfonso (Spain), Adrian P. Banning (UK), Umberto Benedetto (UK), Robert A. Byrne (Germany), Jean-Philippe Collet (France), Volkmar Falk (Germany), Stuart J. Head (The Netherlands), Peter Jüni (Canada), Adnan Kastrati (Germany), Akos Koller (Hungary), Steen D. Kristensen (Denmark), Josef Niebauer (Austria), Dimitrios J. Richter (Greece), Petar M. Seferovi c (Serbia), Dirk Sibbing (Germany), Giulio G. Stefanini (Italy), Stephan Windecker (Switzerland), Rashmi Yadav (UK), Michael O. Zembala (Poland) Document Reviewers: William Wijns (ESC Review Co-ordinator) (Ireland), David Glineur (EACTS Review Co-ordinator) (Canada), Victor Aboyans (France), Stephan Achenbach (Germany), Stefan Agewall (Norway), Felicita Andreotti (Italy), Emanuele Barbato (Italy), Andreas Baumbach (UK), James Brophy (Canada), Héctor Bueno (Spain), Patrick A. Calvert (UK), Davide Capodanno (Italy), Piroze M. Davierwala

3,879 citations

Journal ArticleDOI
TL;DR: A correction has been published: European Heart Journal, ehaa895, https://doi.org/10.1093/eurheartj/ehaa-895.
Abstract: A correction has been published: European Heart Journal, ehaa895, https://doi.org/10.1093/eurheartj/ehaa895

2,361 citations

Journal ArticleDOI
Marco Valgimigli, Héctor Bueno, Robert A. Byrne, Jean-Philippe Collet, Francesco Costa, Anders Jeppsson, Peter Jüni, Adnan Kastrati, Philippe Kolh1, Laura Mauri, Gilles Montalescot, Franz-Josef Neumann, Mate Petricevic, Marco Roffi, Philippe Gabriel Steg, Stephan Windecker, José Luis Zamorano, Glenn N. Levine, Lina Badimon1, Pascal Vranckx, Stefan Agewall, Felicita Andreotti, Elliott M. Antman, Emanuele Barbato, Jean-Pierre Bassand, Raffaele Bugiardini, Mustafa Cikirikcioglu, Thomas Cuisset, Michele De Bonis, Victora Delgado2, Donna Fitzsimons, Oliver Gaemperli, Nazzareno Galiè, Martine Gilard, Christian W. Hamm, Borja Ibanez, Bernard Iung, Stefan James, Juhani Knuuti, Ulf Landmesser, Christophe Leclercq, Maddalena Lettino, Gregory Y.H. Lip, Massimo F Piepoli, Luc Pierard1, Markus Schwerzmann1, Udo Sechtem, Iain A. Simpson, Miguel Sousa Uva, Eugenio Stabile, Robert F. Storey, Michal Tendera, Frans Van de Werf, Freek W.A. Verheugt, Victor Aboyans, Antonio Coca, I M Coman, Veronica Dean, Victoria Delgado, Gerhard Hindricks, Hugo A. Katus, Patrizio Lancellotti1, Theresa McDonagh, Piotr Ponikowski, Dimitrios J. Richter, Evgeny Shlyakhto, Franz Xaver Roithinger, Farid Aliyev, Valeriy Stelmashok, Walter Desmet, Arman Postadzhiyan, Georgios P Georghiou, Zuzana Motovska, Erik Lerkevang Grove, Toomas Marandi, Tuomas Kiviniemi, Sasko Kedev, Steffen Massberg, Dimitrios Alexopoulos, Róbert Gábor Kiss, Ingibjorg Jona Gudmundsdottir, Eugene P. McFadden, Eli I. Lev, Leonardo De Luca, Akhmetzhan Sugraliyev, Edmond Haliti, Erkin M. Mirrakhimov, Gustavs Latkovskis, Birute Petrauskiene, Steve Huijnen, Caroline Jane Magri, Rhizlan Cherradi, Jurriën M. ten Berg, Jan Eritsland, Andrzej Budaj, Carlos Aguiar, Dmitry Duplyakov, Marco Zavatta, Nebojsa M Antonijevic, Zlatko Fras, Antonio Tello Montoliu, Christoph Varenhorst, Dimitri Tsakiris, Faouzi Addad, Sinan Aydogdu, Alexander Parkhomenko, Tim Kinnaird 
TL;DR: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed in collaboration with EACTS is described in this paper.
Abstract: 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS : The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).

1,954 citations